University of Melbourne collaboration with Telix receives Cancer Australia research grant
Melbourne (Australia) – 19th December 2019. Telix Pharmaceuticals Limited (ASX: TLX) is pleased to announce that Telix collaborator Professor Frédéric Hollande from the University of Melbourne Centre
Melbourne (Australia) – 19 Dec 2019
Telix Pharmaceuticals Limited is pleased to announce that Telix collaborator Professor Frédéric Hollande from the University of Melbourne Centre for Cancer Research and colleagues have been successful in their Cancer Australia grant application entitled “The Preclinical Validation of Radio-labelled Girentuximab as a Theranostic Agent in Metastatic Colorectal Cancer”. The successful grant application was announced today by Cancer Australia.
To read full release click here.
Telix Pharmaceuticals Enters Commercial Distribution Agreement for Prostate Cancer Diagnostic
Indianapolis IN and Columbus OH (U.S.A) – 8 April 2020. Telix Pharmaceuticals (U.S.) Inc. is pleased to announce it has...
Telix Pharmaceuticals and partners receive $500K research grant from Government funded Innovative Manufacturing CRC
Melbourne (Australia) – 16 Mar 2020. Telix and partners receive $500K research grant from Government-funded Innovative Manufacturing CRC to advance...
Business Update : COVID-19
Melbourne (Australia) – 13 Mar 2020. Telix provides an update on the Company’s risk management assessment of the novel coronavirus...
Leader in prostate cancer imaging Prof. Frederik L. Giesel joins Scientific Advisory Board
Melbourne (Australia) – 9 March 2020. Telix Pharmaceuticals Limited announces that Professor Dr. Frederik L. Giesel, MD, MBA has joined...
Positive FDA Feedback on NDA Submission Process for TLX591-CDx (kit for the preparation of 68Ga-PSMA-11)
Melbourne (Australia) – 25 Feb 2020. Telix Pharmaceuticals announces that it has received positive feedback from the FDA regarding its...
Telix Pharmaceuticals Releases Annual Report Year Ending 2019
Melbourne (Australia) - 24 Feb 2020. Telix Pharmaceuticals Limited is pleased to provide its Annual Report for the year ending...
European Leadership Changes and Appointment of VP Sales and Marketing, EMEA
Melbourne (Australia) – 21st February 2020. Telix Pharmaceuticals Limited announces that Ms Odile Jaume will be stepping down from her...
Telix completes acquisition of European radiopharmaceutical production facility
Melbourne (Australia) – 3 April 2020. Telix is pleased to announce it has now completed the acquisition of a licensed...